Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,501.65 0.00 0.00%
S&P 500 1,878.61 3.22 0.17%
NASDAQ 4,148.34 21.37 0.52%
Ticker Volume Price Price Delta
STOXX 50 3,189.81 13.84 0.44%
FTSE 100 6,703.00 28.26 0.42%
DAX 9,548.68 4.49 0.05%
Ticker Volume Price Price Delta
NIKKEI 14,404.99 -141.28 -0.97%
TOPIX 1,164.90 -8.91 -0.76%
HANG SENG 22,562.80 53.16 0.24%

OXiGENE Announces Year-End 2012 Earnings Conference Call and Webcast



OXiGENE Announces Year-End 2012 Earnings Conference Call and Webcast

SOUTH SAN FRANCISCO, Calif., March 4, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer, will report year-end 2012 results on Tuesday,
March 12, 2013. A conference call and webcast hosted by OXiGENE management
will begin at 4:30 pm ET (1:30 p.m. PT).

OXiGENE's earnings conference call can be heard live by dialing (888) 841-3431
in the United States and Canada, and +1 (678) 809-1060 for international
callers, five minutes prior to the beginning of the call.

To listen to a live or archived version of the audio webcast, please log on to
the Company's website, www.oxigene.com. Under the "Investors" tab, select the
link to "Events & Presentations."

About OXiGENE

OXiGENE is a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer. The Company's major focus is developing vascular
disrupting agents that selectively disrupt abnormal blood vessels associated
with solid tumor progression. OXiGENE is dedicated to leveraging its
intellectual property and therapeutic development expertise to bring
life-extending and life-enhancing medicines to patients.

The OXiGENE, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=4969

CONTACT: Investor and Media Contact:
         ir@oxigene.com
         650-635-7000

company logo
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement